PaxGenBio Co.,Ltd. of Anyang-si at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

PaxGenBio Co.,Ltd.

#803, 361, Simin-Daero, Dongan-gu Gyeonggi-do, 14057 Anyang-si
Korea, Republic
Telephone +82 31 2445036
Fax +82 31 2445037
info@paxgenbio.com

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Hall map

MEDICA 2021 hall map (Hall 1): stand A33

Fairground map

MEDICA 2021 fairground map: Hall 1

Contact

Brian Lee

General Manager
Marketing & Sales

Phone
+821086197409

Email
brianlee@paxgenbio.com

Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

About us

Company portrait

PaxGenBio Co., Ltd.  was established in 2015 as a molecular diagnostics company that develops, manufactures and markets a portfolio of IVD products targeting infectious diseases and cancers.

PaxGenBio applied its proprietary and chimeric technologies that combine techniques for molecular and immune diagnostics. One of its original technologies, MPCR-ULFA that combines multiplex PCR amplification and universal lateral flow assay (ULFA) enables sensitive, specific, fast, affordable and easy nucleic acid tests that are especially appropriate for applications in low resource settings.

Also, we developed fast SARS-CoV-2 real-time RT-PCR kit detecting the novel corona virus, SARS-CoV-2 by using one-step real-time RT-PCR in a single tube (Run time 50 min, Limit of detection (LoD) : 1 copy/µl (5 copies/reaction)).

Currently, we are developing STI 12 MPCR-ULFA Kit, and we will finish its development within 1st half of next year.

Company data

Export content > 75%
Foundation 2015
Area of business Diagnostic tests